Financials in USD. Standardized financial statements.
A compact view of how Noxopharm Limited turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.40M | $6.01M | $5.43M | $5.61M | $8.28M | $3.75M | $916,534 | $126,299 | $0 |
| Revenue Growth? | -60.1% | +10.7% | -3.2% | -32.3% | +120.8% | +309.2% | +625.7% | 0.0% | 0.0% |
| Cost of Revenue? | $2.94M | $154,534 | $261,513 | $261,722 | $241,445 | $62,098 | $58,885 | $30,256 | $3,346 |
| Gross Profit? | -$534,811 | $5.86M | $5.17M | $5.35M | $8.04M | $3.69M | $857,649 | $96,043 | -$3,346 |
| Gross Margin? | -22.3% | +97.4% | +95.2% | +95.3% | +97.1% | +98.3% | +93.6% | +76.0% | 0.0% |
| Operating Expenses? | $7.00M | $16.44M | $14.95M | $14.35M | $16.12M | $15.60M | $10.44M | $3.20M | $699,720 |
| Operating Income? | -$7.54M | -$16.60M | -$15.21M | -$14.61M | -$16.37M | -$15.67M | -$10.50M | -$3.23M | -$703,070 |
| EBITDA? | -$4.60M | -$14.80M | -$14.95M | -$14.35M | -$7.92M | -$11.86M | -$10.44M | -$3.08M | -$1.05M |
| Income Before Tax | -$3.58M | -$21.04M | -$24.03M | -$8.31M | -$8.24M | -$16.32M | -$19.23M | -$3.17M | -$704,725 |
| Income Tax Expense | $0 | -$5.99M | -$5.37M | $1.04M | -$8.33M | -$3.75M | -$910,518 | -$124,026 | $4 |
| Net Income? | -$3.58M | -$15.06M | -$18.67M | -$9.35M | -$272,093 | -$11.22M | -$18.28M | -$3.05M | -$704,725 |
| EPS? | $-0.01 | $-0.05 | $-0.06 | $-0.04 | $-0.00 | $-0.08 | $-0.15 | $-0.03 | $-0.01 |
| Diluted EPS? | $-0.01 | $-0.05 | $-0.06 | $-0.04 | $-0.00 | $-0.08 | $-0.15 | $-0.03 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality